Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device.
Abbott Laboratories（纽交所：ABT）首席执行官Robert Ford表示公司将利用电视广告和游击营销的混合方式推广其血糖监测器Lingo的美国上市。
This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics.
该设备针对没有糖尿病的消费者，旨在个性化健康数据并增强对其健康指标的理解。
Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits.
此外还阅读了：Similac婴儿奶粉制造商Abbott和Reckitt面临数百起婴儿奶粉诉讼。
Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage.
Ford预计Lingo可以成为一个创造数十亿美元的产品，尽管它仍处于初期阶段。
Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month.
场外交易的Lingo计划在今年上市，与上个月获得FDA认证的Libre Rio一起推出。
Abbott's consumer biowearable, Lingo, is designed for consumers 18 years and older looking to improve their overall health and wellness.
Abbott的消费者生物可穿戴设备Lingo，旨在面向18岁及以上的消费者，帮助他们改善整体健康和健康状况。
Lingo will track glucose and provide personalized insights and customized coaching to help people create healthy habits, retrain their metabolism, and improve their overall well-being.
Lingo将跟踪血糖，并提供个性化见解和定制辅导，帮助人们养成健康的习惯，重新培养代谢，提高整体健康状况。
Libre Rio Libre Rio will be Abbott's first over-the-counter CGM system for people with diabetes in the U.S.
Libre Rio将成为Abbott在美国推出的首个场外CGM系统，适用于患有糖尿病的人。
It is designed for people ages 18 and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
它专为18岁及以上患有2型糖尿病且不使用胰岛素并通常通过生活方式改变管理糖尿病的人设计。
In continuous glucose monitoring, Abbott competes with DexCom Inc (NASDAQ:DXCM) and Medtronic Plc (NYSE:MDT).
在连续血糖监测方面，Abbott与DexCom Inc（纳斯达克股票代码：DXCM）和Medtronic Plc（纽交所股票代码：MDT）竞争。
During the second quarter, FreeStyle Libre, Abbott's prescription blood sugar monitor, achieved $1.6 billion in global sales, up 18.4% year over year.
在第二季度，Abbott的诊方血糖监测仪FreeStyle Libre全球销售额达到160亿美元，同比增长18.4％。
Reuters notes that the company acknowledges that marketing a consumer product like Lingo will differ significantly from promoting a medical device.
据路透社报道，该公司承认推广像Lingo这样的消费品与推广医疗设备有很大不同。
Ford emphasized the importance of guerilla marketing, which includes on-ground outreach and social media campaigns, to drive adoption.
Ford强调了游击营销的重要性，包括现场外联和社交媒体活动，以推动采用。
Sourcing an RBC Capital Markets analyst, Reuters noted that while current sales projections for Abbott and DexCom's OTC products are modest, the potential market is significant.
援引RBC Capital Markets的一位分析师的话，路透社指出，虽然Abbott和DexCom的场外交易产品目前的销售预测是适度的，但潜在市场非常大。
Singh highlighted that Abbott is just beginning to launch Lingo this summer, presenting substantial opportunities for both companies.
辛格（Singh）强调，Abbott刚刚开始在今年夏天推出Lingo，为两家公司提供了巨大的机会。
Ford anticipates that sales growth for Lingo will gradually increase as Abbott establishes the market and learns from its early efforts.
福特预计，随着Abbott确立市场并从早期努力中学到经验，Lingo的销售增长将逐渐增加。
Price Action: ABT stock is up 1.38% at $101.44 at the last check on Friday.
股票价格：ABT股票在上周五最后一次检查时上涨了1.38％，至101.44美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval.
- 礼来公司广受欢迎的减肥药Zepbound在中国获得批准。
Photo via Shutterstock
图片来自shutterstock。